# DexCom, Inc > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/DexCom, Inc). ## Overview DexCom is a U.S. medical device company focused on continuous glucose monitoring systems for people managing diabetes and metabolic health. Its core business is designing, developing, and commercializing CGM products such as Dexcom G7, G7 15 Day, and Stelo, which provide real-time glucose data to patients, caregivers, and clinicians. ## Products & services • Dexcom G7 Continuous Glucose Monitoring System • Dexcom G7 15 Day Continuous Glucose Monitoring System • Stelo over-the-counter glucose biosensor • Disposable sensors and related consumables • Reusable hardware and receiver/accessory components - **Continuous glucose monitoring systems** (97%) — Wearable CGM platforms that measure glucose trends continuously and transmit data to users and clinicians. - **Reusable hardware** (3%) — Reusable transmitters, receivers, and related hardware used with CGM systems. - **Over-the-counter biosensor** (0%) — Stelo is an OTC glucose biosensor sold without a prescription for adults with prediabetes and Type 2 diabetes not using insulin. - Dexcom G7 Continuous Glucose Monitoring System - Dexcom G7 15 Day Continuous Glucose Monitoring System - Stelo OTC glucose biosensor for prediabetes and Type 2 diabetes - Disposable sensors and related consumables - Reusable hardware and accessory components ## Customers DexCom sells primarily to people with diabetes and, increasingly, adults seeking metabolic health monitoring, with clinicians playing a key role in adoption. It also serves caregivers and healthcare professionals such as endocrinologists, physicians, and diabetes educators who recommend, train, and support use of the systems. - **Insulin-using diabetes patients** (primary) — Buy CGM systems to manage glucose in real time and support treatment decisions. - **Non-insulin Type 2 diabetes and prediabetes adults** (primary) — Buy Stelo and related CGM offerings to track metabolic health and behavior changes. - **Healthcare professionals** (secondary) — Recommend, educate, and support CGM adoption because they influence therapy selection and adherence. - **Caregivers and family monitors** (secondary) — Use Dexcom data to help monitor vulnerable patients and improve safety. - People with diabetes who need continuous glucose visibility - Adults with prediabetes or Type 2 diabetes using Stelo - Endocrinologists and physicians who recommend CGM therapy - Diabetes educators who train patients on device use - Caregivers who monitor glucose trends for family members ## Geography DexCom generates most revenue in the United States, with the remainder coming from international markets. The company also maintains direct sales and distribution coverage across North America, Europe, Asia Pacific, and the Middle East, and it expects foreign currency exposure to rise as international operations expand. - **United States** (72%) — Nine months ended September 30, 2025 revenue share - **International** (28%) — Nine months ended September 30, 2025 revenue share - United States is the largest market at 72% of revenue in 2025 YTD - International markets contributed 28% of revenue in 2025 YTD - Direct sales teams operate in North America, Europe, APAC, and the Middle East - Distribution and pharmacy partners extend reach in selected countries - International growth increases foreign currency and reimbursement exposure ## Strategy DexCom is focused on expanding CGM adoption through product innovation, broader access, and stronger commercial execution. Near term, the company is scaling G7 and G7 15 Day, building Stelo as an OTC entry point, and investing in manufacturing and global sales coverage to support demand. - **Scale next-generation CGM platforms** (short-term) — Newer products support customer growth, retention, and competitive differentiation. - **Build Stelo into a new consumer-facing channel** (medium-term) — OTC access broadens the addressable market beyond insulin users. - **Expand global commercial and manufacturing capacity** (medium-term) — Higher demand requires more production, distribution, and local market support. - Expand adoption of G7 and G7 15 Day across diabetes patients - Grow Stelo as an OTC product for metabolic health monitoring - Invest in manufacturing and operations to support demand growth - Strengthen direct sales, education, and distribution coverage - Use R&D to defend product performance and time-to-market ## Risks DexCom faces intense competition from Abbott, Medtronic, and other glucose-monitoring entrants, which can pressure pricing, reimbursement, and market share. Its business also depends on regulatory compliance, product performance, distributor relationships, and cybersecurity protection of sensitive patient and company data. - **Pricing and reimbursement pressure** [high] — Managed care, Medicare, and other payors can reduce reimbursement and force lower net prices. - **Competitive intensity** [high] — Abbott, Medtronic, Roche, and new entrants can compete on technology, price, and distribution. - **Regulatory compliance and product quality** [high] — FDA actions, warning letters, or product issues could lead to restrictions or withdrawal. - **Distributor and pharmacy channel dependence** [medium] — A meaningful share of revenue can flow through third parties that may be hard to replace. - **Cybersecurity and privacy incidents** [medium] — The company stores sensitive patient and business data and relies on connected devices and systems. - Intense competition can pressure pricing and slow share gains - Reimbursement changes can reduce realized prices and margins - Regulatory issues or product problems could restrict sales - Distributor concentration can create revenue volatility - Cybersecurity and privacy breaches could disrupt operations ## Accounting DexCom's reported revenue is heavily driven by disposable sensor sales, so mix shifts between sensors, hardware, rebates, and channel partners can affect recognized revenue and gross margin. Investors should also watch pharmacy rebates, foreign currency effects, and estimates around taxes and contingencies, since management highlights these as judgment-heavy areas that can move earnings. - **Revenue mix between disposable sensors and hardware** — Disposable sensor and other revenue was about 97% of total revenue in 2025 YTD - **Pharmacy rebates** — Can change recognized revenue and period-to-period comparability - **Foreign currency transaction gains and losses** — Affects reported earnings outside core operating performance - **Valuation allowance and uncertain tax positions** — Can materially affect tax expense and effective tax rate - Disposable sensor mix drives most revenue and margin trends - Rebate eligibility and channel mix can reduce net pricing - Pharmacy rebates require estimates and can affect revenue timing - Foreign currency gains and losses affect other income, net - Tax valuation allowances and uncertain tax positions require judgment --- *Last updated: 2026-08-11T04:03:56.228997+00:00*